Cardiac amyloidosis is associated with increased aortic stiffness by Nemes, Attila et al.
R E S E A R CH AR T I C L E
Cardiac amyloidosis is associated with increased aortic stiffness
Attila Nemes MD, PhD, DSc, FESC1 | Dora F€oldeak MD2 |
Peter Domsik MD, PhD1 | Anita Kalapos MD, PhD1 | Arpad Kormanyos MD1 |
Zita Borbenyi MD PhD2 | Tamas Forster MD, PhD, DSc, FESC, FACC1
12nd Department of Medicine and
Cardiology Centre, Medical Faculty, Albert
Szent-Gy€orgyi Clinical Center, University of
Szeged, Szeged, Hungary
2Division of Haematology, 2nd Department
of Medicine and Cardiology Centre, Medical
Faculty, Albert Szent-Gy€orgyi Clinical
Center, University of Szeged, Szeged,
Hungary
Correspondence
Attila Nemes, 2nd Department of Medicine
and Cardiology Center, Medical Faculty,
Albert Szent-Gy€orgyi Clinical Center, Uni-
versity of Szeged, H-6725 Szeged, P.O.
Box 427, Semmelweis street 8, Hungary.
Email: nemes.attila@med.u-szeged.hu
Abstract
Objective: Cardiac amyloidosis (CA) is as an infiltrative disorder primarily caused by extracellular
tissue deposition of amyloid fibrils in the myocardial interstitium. The current study was designed
to test whether alterations in ascending aortic elastic properties could be detected by echocardiog-
raphy in CA patients, and to compare their results to controls.
Patients and methods: We included 19 CA patients from which CA proved to be AL amyloidosis
in 17 cases and transthyretin (TTR) amyloidosis in 2 cases. Their results were compared to 20 age-,
gender-, and risk factor-matched controls.
Results: There was significantly greater interventricular septum and left ventricular (LV) posterior
wall thickness, lower LV ejection fraction and greater E/A in CA patients than in controls, suggest-
ing systolic, and diastolic dysfunction. CA patients also showed significantly reduced aortic strain
and pulsatile change in aortic diameter, and increased aortic stiffness index.
Conclusion: These results suggest increased aortic stiffness in CA patients.
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1 | INTRODUCTION
Cardiac amyloidosis (CA) has been defined as an infiltrative disorder
primarily caused by extracellular tissue deposition of amyloid fibrils in
the myocardial interstitium. There are many types of CA depending on
the precursors that may affect the heart.1,2 Some forms of hereditary
transthyretin-related (TTR) amyloidosis affect the heart almost invaria-
bly, whereas cardiac involvement in light chain amyloidosis (AL) is pres-
ent in about 50% of the cases.1,2 Amyloid involvement of the aorta is
exceedingly rare.3 Theoretically, the aortic wall could be subclinically
infiltrated in CA leading to its stiffening and, consequentially, affecting
left ventricular (LV) function due to altered Windkessel function and
arterial-ventricular coupling.4 Moreover, increased arterial stiffness
have been proposed as one of the potential pathways through which
associated disorders could lead to further cardiovascular abnormalities.
This study was designed to test whether alterations in ascending aortic
elastic properties could be detected by echocardiography in CA
patients, and to compare their results to age-, gender-, and risk factor-
matched controls.
2 | PATIENTS AND METHODS
2.1 | Patient population
The present study included 19 CA patients in whom CA proved to be
AL amyloidosis in 17 cases and transthyretin (TTR) amyloidosis in 2
cases. All CA patients were alive and have been involved into this study
at our tertiary center. Biopsy was performed in all cases to confirm the
diagnosis of CA. The first positive biopsy site was the myocardium in 2
TTR-CA and in 3 AL-CA subjects. In the remaining AL-CA cases, kidney
was the first positive biopsy site in 5 cases, gastrointestinal tract in 4
cases, skin and subcutaneous tissue in 4 cases, bone marrow in 3 cases,
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and salivary gland in 1 case (there were 2 confirmation sites in 3
patients). Routine echocardiographic examination was performed in all
cases, including measurement of wall thickness, and CA was defined in
accordance with the current consensus criteria and practices.5,6 Results
from CA patients were compared to those of 20 age-, gender-, and risk
factor-matched controls. None of the CA patients or control subjects
consumed coffee or tea within 1 hour before combined echocardio-
graphic and blood pressure (BP) measurements. Moreover, none of the
CA patients or control subjects was smoker. The American Diabetes
Association and World Health Organization criteria were used for defi-
nition of diabetes mellitus (DM). Hypertension was defined as either a
systolic or a diastolic elevation of the BP (>140/90 mm Hg) or ongoing
antihypertensive therapy. Hypercholesterolaemia was defined as total
cholesterol level>5.0 mmol/L or current treatment with lipid-lowering
medications. Blood urea nitrogen and creatinine levels were determined
to characterize renal function in CA patients. Each patient gave
informed consent. The study protocol conformed to the ethical guide-
lines of the 1975 Declaration of Helsinki, as reflected in a prior approval
by the human research committee of the University of Szeged.
2.2 | Two-dimensional echocardiography
Complete two-dimensional (2D) transthoracic Doppler echocardiogra-
phy was performed in all cases using a Toshiba Artida echocardiography
equipment (Toshiba, Tokyo, Japan) with a PST-30SBP (1–5 MHz)
phased array transducer in the left lateral decubitus position from multi-
ple windows. All echocardiographic studies were digitally stored and
evaluated by a single expert (AN) who was blinded to the clinical data.
All echocardiographic measurements were averaged from 3 beats.
Modified Simpson’s method was used for LV quantifications.7
2.3 | Measurement of echocardiographic aortic elastic
properties
Aortic elasticity parameters were calculated following a validated
method.8,9 During a routine echocardiographic examination in paraster-
nal long-axis view, an M-mode image was created at a level of 3 cm
above the aortic valve, and systolic and diastolic ascending aortic diam-
eters (SD and DD, respectively) were measured (Figure 1). The Ameri-
can Society of Echocardiography convention as the most accepted
border definition criterion was used in measuring the leading edge of
each layer. The SD and DD were measured at the time of maximum
aortic anterior motion and at the peak of the QRS complex, respec-
tively. At the same time, systolic (SBP) and diastolic (DBP) BP values
were measured in supine position using an automatic cuff mercury
sphygmomanometer on the left arm after 10 minutes of rest.
The following aortic elasticity parameters have been calculated:
 Pulsatile change in aortic diameter (mm)5 SD – DD
 Aortic strain (AS)5 (SD – DD)/DD
 Aortic stiffness index (ASI)5 ln (SBP/DBP)/[(SD – DD)/DD], where
“ln” is the natural logarithm
 Aortic distensibility (AD)52 3 (SD – DD)/[(SBP – DBP) 3 DD]
2.4 | Statistical analysis
All data are presented as mean6 standard deviation. A value of P< .05
was considered to be statistically significant. Independent samples Stu-
dent t test were used to compare continuous variables, and chi-square
test and Fisher’s exact test to compare categorical data. Numerical cor-
relations were established by a Pearson correlation. MedCalc software
was used for statistical calculations (MedCalc, Mariakerke, Belgium).
3 | RESULTS
3.1 | Clinical characteristics
Blood urea nitrogen and creatinine levels were 10.769.4 mmol/L (3.1–
43.9) and 119.16107 mmol/L (44–533), respectively, in CA patients,
demonstrating 3 cases with mild-moderate and 2 cases with severe renal
insufficiency. Clinical data, cardiovascular risk factors, and medications of
CA patients and controls are presented in Table 1. Although none of the
classic cardiovascular risk factors differed significantly between the
groups, control subjects showed higher body mass index (BMI) and SBP
and DBP values at the time of echocardiographic examinations.
3.2 | 2D echocardiographic data
Standard 2D echocardiographic data are summarized in Table 2. No
wall motion abnormalities were found in any CA patients or healthy
FIGURE 1 Measurement of systolic (DS) and diastolic (DD) diameters
of the ascending aorta are shown on the M-mode tracing obtained at a
level 3 cm above the aortic valve at parasternal long-axis view
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subjects. Significant ( grade 3) mitral regurgitation could not be
detected in any of the CA patients or control subjects. Significantly
thickened interventricular septum and LV posterior wall, reduced LV
ejection fraction, and increased E/A, suggesting systolic and diastolic
dysfunction could be detected in CA patients (Table 2).
3.3 | Echocardiographic aortic elastic properties
Significantly reduced aortic strain and pulsatile change in aortic diame-
ter and increased aortic stiffness index could be demonstrated in CA
patients as compared to matched controls (Table 2). From CA patients,
10 were in NYHA I, 3 in NYHA II, 3 in NYHA III, and 3 in NYHA IV
functional classes. The average ASI differed significantly between CA
patients in NYHA classes III-IV and CA patients in classes NYHA I-II
(20.40614.80 vs 9.0568.84, P5 .03). None of other LV and aortic
variables showed difference between CA patients in different func-
tional classes.
3.4 | Correlations
Significant correlations could be detected between ASI and LV end-
diastolic diameter (r5 .45, P5 .05), posterior wall thickness (r5 .49,
P5 .03), and interventricular septum thickness (r5 .46, P5 .05) in CA
patients. None of other aortic data correlated with any LV variable in
CA patients and in controls.
4 | DISCUSSION
CA is caused by extracellular deposition of abnormal amyloid fibrils
within the heart with infiltration occurring in all anatomical struc-
tures.10 To the best of the authors’ knowledge, this is the first echocar-
diographic demonstration of alterations in aortic elastic properties in
CA patients. Most of our CA cases showed AL amyloidosis, where AL
fibrils are derived from monoclonal immunoglobulin light chains with
typical multi-organ infiltration.11 In spite of the progress made over the
past decades in therapy, AL cardiomyopathy remains associated with
poor survival.10 There are several cardiac complications of myocardial
amyloid fibril deposition, the most important being severe congestive
heart failure, atrial fibrillation, ventricular arrhythmias, conduction
abnormalities, orthostatic hypotensive episodes, and autonomic dys-
function.2 In 2 cases, TTR amyloidosis was found, where typical cardiac
manifestations are arrhythmias, syncope or sudden cardiac death, dysp-
noea, and heart failure due to restrictive cardiomyopathy.6
The main finding of the present study was increased ASI and
reduced AS and pulsatile change in aortic diameter in CA patients as
compared to controls. The main cardiovascular risk factors (age, male
TABLE 2 Two-dimensional echocardiographic data of patients with cardiac amyloidosis (CA) and that of controls
CA patients
(n519)
Controls
(n5 20) P
Two-dimensional echocardiography
Left atrial diameter (mm) 46.36 7.2 40.2610.2 .10
Left ventricular end-diastolic diameter (mm) 47.06 5.2 46.263.8 .58
Left ventricular end-systolic diameter (mm) 30.76 5.2 28.963.9 .26
Interventricular septum (mm) 15.16 3.4 9.96 1.1 <.0001
Left ventricular posterior wall (mm) 14.26 2.4 9.76 1.0 <.0001
Left ventricular ejection fraction (%) 59.36 11.7 66.266.7 .03
Mitral annular plane systolic excursion (mm) 12.56 4.4 20.263.5 .01
Systolic aortic diameter (mm) 30.66 4.0 29.863.7 .56
Diastolic aortic diameter (mm) 29.16 3.7 27.663.2 .22
E/A 1.896 1.15 0.8860.21 .0007
Aortic elastic properties
Pulsatile change in aortic diameter (mm) 1.536 1.08 2.2261.04 .05
Aortic strain (AS) 0.0546 0.039 0.08060.036 .04
Aortic distensibility (AD) (cm2/dynes 1026) 2.426 1.49 2.1360.88 .47
Aortic stiffness index (ASI) 12.66 10.7 7.56 3.6 .05
TABLE 1 Clinical characteristics of patients with cardiac amyloido-
sis (CA) and controls
CA patients
(n5 19)
Controls
(n5 20) P
Clinical data
Age (yr) 63.769.1 59.364.1 .06
Male gender (%) 14 (74) 17 (85) .44
Height (m) 170.767.7 162.666.0 .001
Weight (kg) 76.1615.3 89.2617.7 .03
Body mass index (kg/m2) 26.165.0 33.565.6 .0003
Diabetes mellitus (%) 2 (11) 3 (15) 1.00
Hypertension (%) 12 (67) 15 (75) .50
Hypercholesterolaemia (%) 6 (32) 8 (40) .74
Blood pressure values
Systolic blood pressure (mm Hg) 104.3612.9 145.6611.9 <.0001
Diastolic blood pressure (mm Hg) 69.1610.6 89.169.2 <.0001
Aortic pulse pressure (mm Hg) 35.3610.6 60.0610.8 <.0001
Main medications
b-blockers (%) 8 (42) 5 (25) .32
ACE-inhibitors (%) 10 (53) 9 (45) .75
Diuretics (%) 13 (68) 0 (0) .0001
Abbreviation: ACE, angiotensin-converting enzyme.
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gender, DM, hypertension, and hypercholesterolaemia) were similar
between the groups. Although actual BP values at echocardiographic
measurements were higher in controls, aortic elastic properties
appeared significantly impaired in CA patients. Age and BMI were
found to be predictors of increased aortic stiffness in a recent study,12
but BMI was higher in our controls than in our patients with CA.
Several factors could play a role in increased aortic stiffness in CA.
Regarding the literature, amyloid involvement of the aorta is exceedingly
rare.3 However, theoretically together with myocardial tissue, aortic wall
could be infiltrated latently by amyloid fibrils leading to endothelial dys-
function and impairment of its Windkessel function. Most CA patients
had one or more classic cardiovascular risk factors (higher age, male gen-
der, hypertension, DM, or hypercholesterolaemia) which could also have
an effect on arterial stiffness.13 Moreover, ventricular-arterial coupling
and systolic and diastolic LV dysfunction should also be considered when
interpreting these findings.14 CA patients had significantly higher aortic
stiffness in higher NYHA functional classes, suggesting an important role
of aortic stiffness in the development of heart failure in these cases. The
clinical importance of the present study is to draw attention on increased
aortic stiffness and associated reduced functional capacity in CA patients.
However, further clinical studies are warranted to assess the effects of
improvement of vascular elasticity in these cases. Theoretically, all medi-
cal treatments confirmed to improve vascular function and/or heart fail-
ure should be considered in CA patients. Our CA patients were treated
well with b-blockers and ACE-inhibitors, which are known to have posi-
tive effects on arterial stiffness over heart failure.15,16
5 | L IMITATIONS OF THE STUDY
The main limitations of this study are:
 A mixed population of CA patients was examined including both
TTR and AL cases.
 BP measured in the brachial artery may be different from that in the
ascending aorta (central pressure) due to pulse pressure (PP) amplifica-
tion toward the periphery. PP amplification depends on the pulse wave
propagation velocity, which itself is positively but nonlinearly related to
BP. Moreover, gender, age, and body composition have a significant
impact onPPamplification.17However, echocardiography-derived aortic
stiffness data correlatewell with those obtained by invasivemethods.8
 Controls had higher BP values and PP than CA patients, suggesting
better controlled BP in CA patients. This could strengthen our find-
ings since although BP and PP were higher in controls, aortic stiff-
ness was greater in CA patients.
 Measurement of aortic diameter data in systole and diastole was
performed only in one plane. However, it should be considered that
large vessels exhibit nonlinear variations of circumferential stress
and tangent elastic moduli even within the normal pressure range.18
Therefore, aortic elastic properties could theoretically be dissimilar
at different segments of the aorta.
6 | CONCLUSION
Results of the present study suggest increased aortic stiffness in CA
patients than in age-, gender-, and risk factor-matched controls.
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